Teva Pharmaceutical Industries has reported a net income attributable to the company of $630m or $0.74 per share for the first quarter ended 31 March 2013 compared to $859m or $0.97 per share for the first quarter ended 31 March 2012.
Net revenues were $4.9bn for the first quarter of 2013 compared to $5.1bn for the first quarter of 2012.
Teva president and chief executive officer Dr. Jeremy Levin said the company is pleased by the overall performance of its specialty products and results of OTC joint venture during the first quarter.
"Our generic operations, which are a core component of our business, performed in line with our expectations and were particularly strong in Western and Eastern Europe," Levin added.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/teva-reports-decreased-q1-net-income-060513
